“How do you act as a good corporate citizen and disclose, without jeopardizing the unknown?” As the closing keynote speaker for the first day of Citeline’s two-day TrialScope EXTRA event, Ali Pashazadeh, Treehill Partners CEO, discussed a topic frowned upon by the disclosure experts in the room: noncompliance. He shared candid insights on clinical trial disclosure compliance and its relation to intellectual property (IP) and patents. Here’s the details published in Citeline:
https://www.citeline.com/en/resources/impact-of-clinical-trial-disclosure-on-ip